Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
COOL Corner Growth Acquisition Corp
FSRXW FinServ Acquisition II Equity Warrant Exp 17 Feb 2026 *W EXP 02/17/2026
KVSC Khosla Ventures Acquisition III Co
FRPH FRP Holdings Inc
TSLA Tesla Inc
DOMO Domo Inc
PGP PIMCO Global StocksPLUS and Income Fund
CZOO+ Cazoo Group Equity Warrants Exp 26th Aug 2026 *W EXP 08/26/2026
TZPSW TZP Strategies Acquisition Equity Warrant 06 Jan 2026 *W EXP 01/06/2026
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.

Premarket

Last Trade
Delayed
$608.95
5.76 (0.95%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$603.19
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
673

10-day average volume:
844,625
673
Annual Earnings Met Consensus (Year ending 12/2020)Next Earnings Announcement
Annual
Announced February 5, 2021
$31.47Annual Estimate range
of 25 analysts
$27.79 to $33.252021 Earnings
will announce
February 4, 2022

Annual Earnings History and Estimates

Show high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

REGN's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.